Mitsue Kurasawa

TL;DR: The clinical benefit of combination therapy with pertuzumab and trastuzumAB for patients with HER2-positive gastric cancers is suggested, through the potentiation of cell growth inhibition, apoptosis activity, cell killing activity by ADCC, and antiangiogenic activity.

TL;DR: Results suggest that the synergistic antitumor activity of paclitaxel and bevacizumab in combination may be a result of the increase in pac litaxel concentration in tumor resulting from the downregulation of vascular permeability when co-administered with bevaccizumAB.

TL;DR: The erlotinib plus bevacizumab combination demonstrated promising efficacy in the B901L xenograft model of EGFR Mut+ NSCLC and elucidated the mode of action of this combination.

TL;DR: Results indicate that irinotecan may enhance the effect of T cell activation caused by anti-PD-L1 treatment by reducing Tregs and augmenting MHC class I–mediated tumor antigen presentation, and concurrent upregulation of PD-L 1 expression can be blocked by the anti- PD- L1 antibody.

TL;DR: Adding BEV to ERL did not enhance antitumor activity in primarily ERL‐resistant tumors with T790M mutation; however, BEV+ERL enhanced antitumors activity in T790m mutation‐ or MET amplification‐positive tumors as long as their growth remained significantly suppressed by ERL.